Domů › Metastatický karcinom › Oklahoma › Oklahoma City
Klinické studie Metastatický karcinom v Oklahoma City, OK
16 studií pro Metastatický karcinom hledá účastníky v lokalitách v Oklahoma City a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Probíhá náborFáze 1/2
- Avenzo Therapeutics Recruiting Site, Oklahoma City
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Probíhá náborFáze 2
- University of Oklahoma Health Sciences Center, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Probíhá náborFáze 1/2
- University of Oklahoma, Oklahoma City
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Probíhá náborFáze 1
- University of Oklahoma Health Sciences Center, Oklahoma City
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Probíhá náborFáze 3
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Probíhá náborFáze 1/2
- University of Oklahoma, Oklahoma City
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Probíhá náborFáze 2
- University of Oklahoma Health Sciences Center, Oklahoma City
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Probíhá náborFáze 1
- University of Oklahoma - Health Sciences Center, Oklahoma City
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
Probíhá náborFáze 1
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Probíhá náborFáze 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1/2
- Stephenson Cancer Center, Oklahoma City
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Probíhá náborFáze 1/2
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
Probíhá náborObservační studie
- Mercy Hospital Oklahoma City, Oklahoma City
Circulating Tumor DNA Response In Urothelial Cancer
Probíhá náborFáze 2
- OU Health Stephenson Cancer Center, Oklahoma City
Spine Radiosurgery for Symptomatic Metastatic Neoplasms
Probíhá náborFáze 2
- OU Health Stephenson Cancer Center, Oklahoma City
A Study of NX-1607 in Adults With Advanced Malignancies
Probíhá náborFáze 1
- University of Oklahoma, Oklahoma City
Studie Metastatický karcinom v jiných městech
- Houston, TX104 studií
- New York City, NY93 studií
- Nashville, TN70 studií
- Boston, MA63 studií
- Los Angeles, CA57 studií
- St. Louis, MO54 studií
- Arlington, VA53 studií
- Philadelphia, PA46 studií
- Chicago, IL45 studií
- San Antonio, TX44 studií
- Washington, DC43 studií
- Dallas, TX42 studií
Další studie v Oklahoma City
- Nemalobuněčný plicní karcinom28 studií
- Rakovina vaječníků28 studií
- Rakovina endometria25 studií
- Kolorektální karcinom22 studií
- Rakovina prostaty21 studií
- Rakovina plic19 studií
- Rakovina prsu17 studií
- Rakovina (všechny typy)14 studií
- Akutní myeloidní leukemie14 studií
- Squamózní buněčný karcinom hlavy a krku13 studií
- Rakovina močového měchýře11 studií
- Rakovina slinivky břišní11 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.